Radiopharmaceutical CDMO Market Size & Trends Report Segmented by Type (Technetium-99m, Fluorine-18, Leutetium-177, Gallium-68, Actinium-225), Application (Diagnostic, Therapeutic), Phase (Pre-clinical, Clinical, Commercial), Indication (Cardiology, Oncology, Neurology) & Regional Forecasts to 2030

Global Radiopharmaceutical CDMO Market Segmentation

This report by Medi-Tech Insights provides thesize of the global radiopharmaceutical CDMO market at theregional- and country-level from 2023 to 2030. The report further segments the market based on radiopharmaceutical type, application, phase, and indication.

Market Size & Forecast (2023-2030), By Radiopharmaceutical Type, USD Million

• Technetium-99m
• Fluorine-18
• Leutetium-177
• Gallium-68
• Actinium-225
• Others

Market Size & Forecast (2023-2030), By Application, USD Million

• Diagnostic Radiopharmaceuticals
  • PET Radiopharmaceuticals
  • SPECT Radiopharmaceuticals
• Therapeutic Radiopharmaceuticals
  • Alpha Emitters
  • Beta Emitters
  • Other Thpharmaceuticals

Market Size & Forecast (2023-2030), By Phase, USD Million

• Pre-clinical
• Clinical
• Commercial

Market Size & Forecast (2023-2030), By Indication, USD Million

• Oncology
• Cardiovascular Disorders
• Neurological Disorders
• Others

Market Size & Forecast (2023-2030), By Region, USD Million

• North America
  • US
  • Canada
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Rest of Asia Pacific
• Latin America
• Middle East & Africa